Synopsis: A large, randomized, double-blind, multicenter, noninferiority trial revealed consistent superiority in exacerbation reduction, functional respiratory improvement, and quality-of-life indices in certain COPD patients treated with combination long-acting beta-agonist and long-acting muscarinic antagonist when compared with the standard long-acting beta-agonist and inhaled corticosteroid therapy that is commonly prescribed.
Reference: Wedzicha JA, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
Disclosure: The authors declare that they have no conflicts of interest.